|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Roberts, J. S., S. A. LaRusse, H. Katzen, P. J. Whitehouse, M. Barber, S. G. Post, N. Relkin, K. Quaid, R. H. Pietrzak, A. Cupples, L. A. Farrer, T. Brown, and R. C. Green. 2003. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Disease & Associated Disorders 17(2):86-93. Schumpeter, J. A. 1911. The theory of economic development: An inquiry into profits, capital, credit, interest, and the business cycle. Cambridge, MA: Harvard University Press. Shak, S. 2007. Introducing a genomic innovation to clinical practice. Presentation at the Institute of Medicine workshop on diffusion of genomic innovations in health and medicine. December 4. Washington, DC. Trusheim, M. R., E. R. Berndt, and F. L. Douglas. 2007. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 6(4):287-293. Varmus, N. 2002. Getting ready for gene-based medicine. New England Journal of Medicine 347(19):1526-1527. Veenstra, D. L., M. K. Higashi, and K. A. Phillips. 2000. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2(3):Article 29. http://www.aapsj.org/view.asp?art=ps020329 (accessed February 13, 2008).
|
|
|||||||||||||||
